Description
ADSTILADRIN NADOFARAGENE FIRADENOVEC-VNCG
First action · last action
2023-11-22 · 2023-11-22
Transactions
1
First transaction's obligation
$45,829
Base + all options value (sum of deltas)
$45,829
Extent competed
NOT COMPETED
Other than full & open authority
ONLY ONE SOURCE-OTHER (FAR 6.302-1 OTHER)
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2023-11-22+$45,829= $45,829
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2023-11-22 | +$45,829 | $45,829 | ADSTILADRIN NADOFARAGENE FIRADENOVEC-VNCG |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI HJ39FBLVE7L5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25026P0991 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $43,680 | FY2026 |
| 36C26226P1412 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $38,220 | FY2026 |
| 36C24826P1108 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $54,600 | FY2026 |
| 36C24226P0845 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $46,019 | FY2026 |
| 36C24926P0361 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $36,814 | FY2026 |
| 36C24226P0588 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $46,019 | FY2026 |
Other recipients under 6505 from 256-NETWORK CONTRACT OFFICE 16 (36C256) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C25626N0555 | CARDINAL HEALTH 414, LLC | 256-NETWORK CONTRACT OFFICE 16 (36C256) | $654,692 | FY2026 |
| 36C25626P0618 | HANGER PROSTHETICS & ORTHOTICS INC | 256-NETWORK CONTRACT OFFICE 16 (36C256) | $15,119 | FY2026 |
| 36C25626N0492 | BAYER HEALTHCARE PHARMACEUTICALS INC | 256-NETWORK CONTRACT OFFICE 16 (36C256) | $386,860 | FY2026 |
| 36C25626N0469 | CARDINAL HEALTH 414, LLC | 256-NETWORK CONTRACT OFFICE 16 (36C256) | $396,000 | FY2026 |
| 36C25626N0461 | CARDINAL HEALTH 414, LLC | 256-NETWORK CONTRACT OFFICE 16 (36C256) | $271,226 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C25624P0263_3600_-NONE-_-NONE- · retrieved 2026-09-26.